|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
anticholinergic agent
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1986
gptkb:United_States
|
|
gptkbp:brand
|
Atrovent
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
gptkb:sneaker
prostatic hypertrophy
hypersensitivity to ipratropium
|
|
gptkbp:developed_by
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:dosage_form
|
inhalation aerosol
inhalation solution
|
|
gptkbp:formulation
|
gptkb:software_framework
aerosol
nebulizer solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ipratropium bromide
|
|
gptkbp:ingredients
|
C20 H30 Br N2 O3 S
|
|
gptkbp:interacts_with
|
other anticholinergic drugs
beta-adrenergic agonists
|
|
gptkbp:is_atype_of
|
R03 B B01
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
gptkb:asthma
chronic obstructive pulmonary disease
|
|
gptkbp:manager
|
inhalation
|
|
gptkbp:marketed_as
|
gptkb:government_agency
gptkb:Australia
gptkb:Brazil
gptkb:India
gptkb:Italy
gptkb:Japan
gptkb:Monarch
gptkb:Spain
gptkb:United_Kingdom
gptkb:Native_American_tribe
|
|
gptkbp:packaging
|
gptkb:superhero
vial
nebulizer kit
|
|
gptkbp:pharmacokinetics
|
excretion primarily in urine
half Life 1.5 hours
bioavailability 2% to 7%
|
|
gptkbp:related_to
|
respiratory therapy
bronchodilator therapy
anticholinergic bronchodilators
ipratropium bromide and albuterol
tiotropium
|
|
gptkbp:safety_features
|
Category B
|
|
gptkbp:side_effect
|
headache
cough
dry mouth
|
|
gptkbp:type_of
|
188150-94-8
|
|
gptkbp:bfsParent
|
gptkb:Combivent_Respimat
|
|
gptkbp:bfsLayer
|
6
|